Recent searches
    Trending searches
    AMGN logo Amgen +
    Amgen
    +
    Revenue breakdown by Products & Services
    Revenue breakdown by Geography

    Amgen's Revenue by Segment

    In fiscal year 2024, Amgen's revenue by segment (products & services) are as follows:

    • Aranesp: $1.34 B
    • BLINCYTO: $1.22 B
    • ENBREL: $3.32 B
    • EVENITY: $1.56 B
    • KRYSTEXXA: $1.19 B
    • Kyprolis: $1.50 B
    • Nplate: $1.46 B
    • Otezla: $2.13 B
    • Prolia: $4.37 B
    • Repatha (evolocumab): $2.22 B
    • TEPEZZA: $1.85 B
    • TEZSPIRE: $972.00 M
    • Vectibix: $1.05 B
    • XGEVA: $2.23 B

    Learn more about Amgen’s Revenue by Geography

    Check out competitors to Amgen in a side-by-side comparison.

    Explore additional financial metrics for Amgen.

    Continue reading...

    The above chart shows Amgen's revenue percentage share by segment (products and services).

    In fiscal year 2022, Amgen's revenue by segment is as follows:

    • Human Therapeutics generated $24.80 B in revenue, representing 94.22% of its total revenue.
    • Other generated $1.52 B in revenue, representing 5.78% of its total revenue.

    The biggest segment for Amgen is the Human Therapeutics, which represents 94.22% of its total revenue.
    The smallest segment for Amgen is the Other, which represents 5.78% of its total revenue.

    The above chart shows Amgen's revenue percentage share by segment (products and services).

    In fiscal year 2023, Amgen's revenue by segment is as follows:

    • Human Therapeutics generated $26.91 B in revenue, representing 95.46% of its total revenue.
    • Other generated $1.28 B in revenue, representing 4.54% of its total revenue.

    The biggest segment for Amgen is the Human Therapeutics, which represents 95.46% of its total revenue.
    The smallest segment for Amgen is the Other, which represents 4.54% of its total revenue.

    The above chart shows Amgen's revenue percentage share by segment (products and services).

    In fiscal year 2024, Amgen's revenue by segment is as follows:

    • Aranesp generated $1.34 B in revenue, representing 5.08% of its total revenue.
    • BLINCYTO generated $1.22 B in revenue, representing 4.61% of its total revenue.
    • ENBREL generated $3.32 B in revenue, representing 12.56% of its total revenue.
    • EVENITY generated $1.56 B in revenue, representing 5.92% of its total revenue.
    • KRYSTEXXA generated $1.19 B in revenue, representing 4.49% of its total revenue.
    • Kyprolis generated $1.50 B in revenue, representing 5.69% of its total revenue.
    • Nplate generated $1.46 B in revenue, representing 5.52% of its total revenue.
    • Otezla generated $2.13 B in revenue, representing 8.05% of its total revenue.
    • Prolia generated $4.37 B in revenue, representing 16.57% of its total revenue.
    • Repatha (evolocumab) generated $2.22 B in revenue, representing 8.42% of its total revenue.
    • TEPEZZA generated $1.85 B in revenue, representing 7.01% of its total revenue.
    • TEZSPIRE generated $972.00 M in revenue, representing 3.68% of its total revenue.
    • Vectibix generated $1.05 B in revenue, representing 3.96% of its total revenue.
    • XGEVA generated $2.23 B in revenue, representing 8.43% of its total revenue.

    The biggest segment for Amgen is the Prolia, which represents 16.57% of its total revenue.
    The smallest segment for Amgen is the TEZSPIRE, which represents 3.68% of its total revenue.
    Continue reading...

    Summary Table

    Products & Services (Percent Share) 2022 2023 2024
    Other 5.78% 4.54% -
    Human Therapeutics 94.22% 95.46% -
    TEPEZZA - - 7.01%
    XGEVA - - 8.43%
    Vectibix - - 3.96%
    TEZSPIRE - - 3.68%
    Aranesp - - 5.08%
    Repatha (evolocumab) - - 8.42%
    Prolia - - 16.57%
    Otezla - - 8.05%
    Nplate - - 5.52%
    Kyprolis - - 5.69%
    KRYSTEXXA - - 4.49%
    EVENITY - - 5.92%
    ENBREL - - 12.56%
    BLINCYTO - - 4.61%
    Total Revenue 100% 100% 100%

    The above chart shows the revenue trend of different segments of Amgen.

    In fiscal year 2024, the Prolia generated the most revenue ($4.37 B), and the TEZSPIRE generated the least revenue ($972.00 M).

    The above chart shows growth drivers and a year-over-year comparison of different segments' revenue.

  • Aranesp revenue increased 100% ($1.34 B) from $0.00 (in 2023) to $1.34 B (in 2024).
  • BLINCYTO revenue increased 100% ($1.22 B) from $0.00 (in 2023) to $1.22 B (in 2024).
  • ENBREL revenue increased 100% ($3.32 B) from $0.00 (in 2023) to $3.32 B (in 2024).
  • EVENITY revenue increased 100% ($1.56 B) from $0.00 (in 2023) to $1.56 B (in 2024).
  • Human Therapeutics revenue decreased -100% ($26.91 B) from $26.91 B (in 2023) to $0.00 (in 2024).
  • KRYSTEXXA revenue increased 100% ($1.19 B) from $0.00 (in 2023) to $1.19 B (in 2024).
  • Kyprolis revenue increased 100% ($1.50 B) from $0.00 (in 2023) to $1.50 B (in 2024).
  • Nplate revenue increased 100% ($1.46 B) from $0.00 (in 2023) to $1.46 B (in 2024).
  • Otezla revenue increased 100% ($2.13 B) from $0.00 (in 2023) to $2.13 B (in 2024).
  • Other revenue decreased -100% ($1.28 B) from $1.28 B (in 2023) to $0.00 (in 2024).
  • Prolia revenue increased 100% ($4.37 B) from $0.00 (in 2023) to $4.37 B (in 2024).
  • Repatha (evolocumab) revenue increased 100% ($2.22 B) from $0.00 (in 2023) to $2.22 B (in 2024).
  • TEPEZZA revenue increased 100% ($1.85 B) from $0.00 (in 2023) to $1.85 B (in 2024).
  • TEZSPIRE revenue increased 100% ($972.00 M) from $0.00 (in 2023) to $972.00 M (in 2024).
  • Vectibix revenue increased 100% ($1.05 B) from $0.00 (in 2023) to $1.05 B (in 2024).
  • XGEVA revenue increased 100% ($2.23 B) from $0.00 (in 2023) to $2.23 B (in 2024).
    • Continue reading...

    Summary Table

    Products & Services 2022
    Value Change
    		2023
    Value Change
    		2024
    Value Change
    Aranesp - - - - $1.34 B -
    BLINCYTO - - - - $1.22 B -
    ENBREL - - - - $3.32 B -
    EVENITY - - - - $1.56 B -
    Human Therapeutics $24.80 B - $26.91 B
    8.50%
    		- -
    KRYSTEXXA - - - - $1.19 B -
    Kyprolis - - - - $1.50 B -
    Nplate - - - - $1.46 B -
    Otezla - - - - $2.13 B -
    Other $1.52 B - $1.28 B
    15.90%
    		- -
    Prolia - - - - $4.37 B -
    Repatha (evolocumab) - - - - $2.22 B -
    TEPEZZA - - - - $1.85 B -
    TEZSPIRE - - - - $972.00 M -
    Vectibix - - - - $1.05 B -
    XGEVA - - - - $2.23 B -
    Total Revenue $26.32 B - $28.19 B
    7.09%
    		$26.40 B
    6.36%

    Related company

    Related

    Submit feedback to Bullfincher